AstraZeneca's SWOT analysis: pharma giant's stock poised for growth amid challenges
AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...
The Sunday Business Post2h
Mounting ‘challenges’ force AstraZeneca to cut jobs at Dublin office, internal letter shows
The move comes as the company faces ‘several challenges’ around the launching of medicines and timed out patents ...
Zacks.com on MSN1d
Should AstraZeneca Stock Be in Your Portfolio Pre-Q4 Earnings?
AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...
‘I was desperate for the AstraZeneca vaccine to succeed. Then I became alarmed by what I saw’
Haematologist Dr Sue Pavord was one of the jab’s biggest supporters, but she knew something was wrong when she saw the ...
BioPharma Dive13h
Enhertu, with new OK, set to supplant chemo in HER2-low breast cancer
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
FiercePharma3h
Sanofi's RSV antibody Beyfortus, after smashing blockbuster sales threshold, still has room to grow in US: execs
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
AstraZeneca PLC ADR rises Monday, outperforms market
The AstraZeneca PLC ADR AZN rallied 1.48% to $70.08 Monday, on what proved to be an all-around mixed trading session for the ...
BioSpace2d
AstraZeneca, Daiichi Sankyo Continue ADC Rally With Enhertu Expansion
Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...
AstraZeneca rises Wednesday, outperforms market
AstraZeneca PLC closed 16.10% below its 52-week high of £133.88, which the company reached on September 3rd.
AstraZeneca, Daiichi’s drug cleared for wider use in breast cancer patients in US
Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the ...
AstraZeneca To Pump $570 Million Into Canada, Driving Expansion, Job Growth
AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines ...
Pharm Exec2d
FDA Approves AstraZeneca, Daiichi Sankyo’s Enhertu for Unresectable or Metastatic Hormone Receptor-Positive, HER2-Low Breast Cancer
Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, ...